NCT03778229进行中（未招募）2 期
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- AstraZeneca
- 入组人数
- 367
- 试验地点
- 90
- 主要终点
- Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set
研究概览
简要总结
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
详细描述
The combination of osimertinib with savolitinib in this study (the SAVANNAH study) will explore if the combination will overcome MET-amplification as a mechanism of resistance. The SAVANNAH study will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET-amplified/overexpressed, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib.
Eligible patients will be those with histologically or cytologically confirmed diagnosis of EGFRm+, MET amplified/overexpressed (FISH10+ and/or IHC90+) NSCLC that is locally advanced or metastatic and is not amenable to further surgery or radiotherapy with curative intent. The disease must have progressed following treatment with first line osimertinib. Patients must have confirmation of MET-amplified/overexpressed tumour by central FISH and IHC testing (requirements summarised in the main body of the protocol and fully explained in the Central Laboratory Manual). Patients must not have received prior or current treatment with savolitinib or another MET inhibitor.
All patients confirmed as eligible will begin treatment on Day 1 with osimertinib + savolitinib combination therapy or placebo to osimertinib + savolitinib. Treatment will continue in 28 day cycles until either objective disease progression by investigator per RECIST 1.1 is assessed, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65+ years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be ≥18 years of age (≥20 years of age in Japan). All genders are permitted.
- •Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.
- •Documented radiologic disease progression on 1L osimertinib.
- •MET amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment.
- •Available tumour sample for central MET FISH and IHC analysis or willingness to collect additional sample for central testing which fulfils the following requirements:
- •Obtained following progression on previous osimertinib therapy;
- •obtained within 2 years of submission for MET analysis;
- •sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual.
- •At least 1 lesion, not previously irradiated, not biopsied during the screening period, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with CT or MRI which is suitable for accurate repeated measurements. If only 1 measurable lesion exists, it is acceptable to be used as long as baseline tumour assessment scans are done at least 14 days after the screening tumour sample collection is performed.
- •Prior lines of therapy in locally advanced/metastatic setting: Only prior 1L osimertinib treatment in metastatic setting is permitted.
- •Adequate haematological function defined as:
- •Absolute neutrophil count ≥1500/μL
- •Haemoglobin ≥9 g/dL (no transfusion in the past 2 weeks)
- •Platelets ≥100,000/μL (no transfusion in the past 10 days)
- •Adequate liver function
- •ALT, AST ≤2.5 x ULN with TBL ≤ ULN OR
- •TBL >ULN to ≤1.5x ULN with ALT and AST ≤ ULN
- •Adequate renal function - defined as a serum creatinine <1.5 times the institutional ULN OR a glomerular filtration rate ≥50 mL/min. Confirmation of creatinine clearance is only required when creatinine is only required when creatinine is >1.5 times ULN.
- •Adequate coagulation parameters: INR <1.5 and activated partial thromboplastin time <1.5 x ULN unless patients are receiving therapeutic anti coagulation which affects these parameters.
- •Patients with known tumour thrombus or deep vein thrombosis are eligible if clinically stable on low molecular weight heparin for ≥2 weeks. The use of direct oral anticoagulants such as apixaban/rivaroxaban will be accepted as treatment for cancer related thromboembolism treatment. The use of warfarin for oral anticoagulation is not recommended.
- •ECOG/WHO performance status of 0 or 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
- •Females must be using highly effective contraceptive measures, should not be breast feeding and must have a negative pregnancy test if of childbearing potential, or must have evidence of non-childbearing potential.
- •Males with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 6 months following discontinuation of study drug.
排除标准
- •Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum therapy related neuropathy.
- •As judged by the investigator, active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhoea Grade ≥2, malabsorption syndrome or previous significant bowel resection).
- •Any of the following cardiac diseases currently or within the last 6 months:
- •Unstable angina pectoris
- •Congestive heart failure (New York Heart Association [NYHA] ≥Grade 2)
- •Acute myocardial infarction
- •Stroke or transient ischemic attack
- •Uncontrolled hypertension (blood pressure [BP] ≥150/95 mmHg despite medical therapy).
- •Mean resting correct QT interval (QTcF) >470 msec for women and >450 msec for men at Screening, obtained from 3 ECGs using the screening clinic ECG machine derived QTcF value.
- •Any factors that may increase the risk of QTcF prolongation or risk of arrhythmic events such as heart failure, chronic hypokalaemia not correctable with supplements, congenital or familial long QT syndrome, family history of unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes.
- •Any clinically important abnormalities in rhythm, conduction or morphology of resting ECGs, eg, complete left bundle branch block, third degree heart block, second degree heart block, P-R interval >250 msec.
- •Acute coronary syndrome
- •Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study drug or has not recovered from side effects of such therapy.
- •Major surgical procedures ≤28 days of beginning study drug or minor surgical procedures ≤7 days
- •Evidence of severe or uncontrolled systemic diseases, including renal transplant, active bleeding diatheses or uncontrolled hypertension, which in the investigator's opinion makes it undesirable for the patient to participate
- •Active hepatitis B or C or known serious active infection e.g. tuberculosis or human immunodeficiency virus. Viral testing is not required for assessment of eligibility for the study.
- •Known serious active infection including, but not limited to, tuberculosis, or human immunodeficiency virus (positive human immunodeficiency virus 1/2 antibodies).
- •Presence of other active cancers, or history of treatment for invasive cancer, within the last 5 years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
- •Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks prior to start of study treatment.
- •Past medical history of interstitial lung disease(ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- •History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement, with or without normal LFTs,
- •Prior or current treatment with a 3rd generation EGFR-TKI other than osimertinib
- •Prior or current treatment with savolitinib or another MET inhibitor (eg, foretinib, crizotinib, cabozantinib, onartuzumab, capmatinib).
- •Any cytotoxic chemotherapy, investigational agents or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days prior to the first dose of study treatment with the exception of monotherapy osimertinib which may continue uninterrupted during screening.
- •Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4, strong inhibitors of CYP1A2 within 3 weeks of the first dose of study treatment (including St John's Wort).
- •Participation in another clinical study with a cytotoxic, investigational product (IP), or other anticancer drug for the treatment of advanced NSCLC if received IP from that study within 14 days of the first dose of study treatment.
- •Known hypersensitivity to the active or inactive excipients of osimertinib or savolitinib or drugs with a similar chemical structure or class.
研究组 & 干预措施
osimertinib + savolitinib
Experimental
osimertinib + savolitinib
干预措施: osimertinib (Drug)
osimertinib + savolitinib
Experimental
osimertinib + savolitinib
干预措施: savolitinib (Drug)
placebo + savolitinib
Placebo Comparator
placebo + savolitinib
干预措施: savolitinib (Drug)
placebo + savolitinib
Placebo Comparator
placebo + savolitinib
干预措施: placebo (Drug)
结局指标
主要结局
Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set
时间窗: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.
Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.
Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set
时间窗: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years.
Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.
次要结局
- Objective Response Rate (ORR) by BICR Assessment; Target Population Analysis Set(Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years.)
- Duration of Response (DoR) by Investigator Assessment; Target Population Analysis Set(From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.)
- Duration of Response (DoR) by BICR Assessment; Target Population Analysis Set(From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.)
- Progression-free Survival (PFS) by Investigator Assessment; Target Population Analysis Set(Time from randomization/start of study treatment to investigator assess progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.)
- Progression-free Survival (PFS) by BICR Assessment; Target Population Analysis Set(Time from randomization/start of study treatment to BICR assessed progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.)
- Overall Survival (OS); Target Population Analysis Set(Time from randomization/start of study treatment to all-cause death, assessed for up to 5.6 years.)
- Objective Response Rate (ORR) by Investigator Assessment; Contribution of Components Analysis Set(Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.)
- Objective Response Rate (ORR) by BICR Assessment; Contribution of Components Analysis Set(Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.)
- Duration of Response (DoR) by Investigator Assessment; Contribution of Components Analysis Set(From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.)
- Duration of Response (DoR) by BICR Assessment; Contribution of Components Analysis Set(From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.)
- Progression-free Survival (PFS) by BICR Assessment; Contribution of Components Analysis Set(Time from randomization/start of study treatment to BICR assessed progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.)
- Progression-free Survival (PFS) by Investigator Assessment; Contribution of Components Analysis Set(Time from randomization/start of study treatment to investigator assess progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.)
- Objective Response Rate (ORR) by Investigator Assessment; Safety Analysis Set(Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.)
- Objective Response Rate (ORR) by BICR Assessment; Safety Analysis Set(Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.)
- Duration of Response (DoR) by Investigator Assessment; Safety Analysis Set(From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.)
- Duration of Response (DoR) by BICR Assessment; Safety Analysis Set(From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.)
- Overall Survival (OS); Safety Analysis Set(Time from randomization/start of study treatment to all-cause death, assessed for up to 5.6 years.)
- Progression-free Survival (PFS) by Investigator Assessment; Safety Analysis Set(Time from randomization/start of study treatment to investigator assess progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.)
- Progression-free Survival (PFS) by BICR Assessment; Safety Analysis Set(Time from randomization/start of study treatment to BICR assessed progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.)
研究者
AstraZeneca Clinical Study Information Center
Scientific
AstraZeneca AB
研究点 (90)
Loading locations...
相似试验
招募中
2 期
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersMetastatic Non-small Cell Lung CancerNCT04410796Memorial Sloan Kettering Cancer Center571
已完成
2 期
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsNon Small Cell Lung CancerNCT03434418Duke University17
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerNon-small Cell Lung CancerNCT03392246Dana-Farber Cancer Institute25
已完成
1 期
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersEGFR-mutant Lung CancersNon-small Cell Lung CancerNCT02803203Memorial Sloan Kettering Cancer Center49
尚未招募
2 期
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.Non Small Cell Lung CancerEGFR Gene MutationNCT06018688Daping Hospital and the Research Institute of Surgery of the Third Military Medical University44